{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:09:03Z","timestamp":1794002943382,"version":"4.8.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a complex etiology that affects the large intestine. Characterized by chronic, bloody diarrhea, UC can lead to severe complications, including an increased risk of colorectal cancer. Despite advancements in conservative treatment, including biologics like anti-TNF agents and ustekinumab (UST), many patients do not achieve full remission. Dual targeted therapy (DTT) combining infliximab (IFX) and UST is a promising approach to improve treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective, randomized, multicenter, head-to-head controlled trial will evaluate the efficacy and safety of UST, IFX, and combination therapy (UST\u2009+\u2009IFX) in 172 patients with moderate to severe active UC across eight gastroenterology centers in Poland. The study includes a 14\u201316\u2009week remission induction period followed by a 52-week maintenance phase. Patients will be randomly assigned to one of three treatment arms: IFX monotherapy, UST monotherapy, or IFX\u2009+\u2009UST combination therapy. Primary endpoint is clinical and endoscopic remission post-induction. Secondary endpoints include clinical response, biochemical remission, histological remission, and quality of life assessments using the Inflammatory Bowel Diseases Questionnaire and 36-Item Short Form Survey. Safety will be monitored through adverse event and serious adverse event reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This trial aims to determine whether combining IFX and UST can achieve higher remission rates and better long-term outcomes compared to monotherapy. The results could provide crucial insights into the optimal use of biologic agents in UC treatment, potentially establishing DTT as a standard therapy. The study\u2019s design, including extensive follow-up and robust endpoint measures, will contribute to understanding the therapeutic potential and safety profile of this combination therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1458998","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:36:27Z","timestamp":1726720587000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis \u2013 a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Renata","family":"Talar-Wojnarowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Fabisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Zatorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"P\u0142oszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"B\u0142aziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Rydzewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Ma\u0142ecka-Wojciesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/pg.2023.125882","article-title":"Guidelines for the management of ulcerative colitis. Recommendations of the polish Society of Gastroenterology and the polish National Consultant in gastroenterology","volume":"18","author":"Eder","year":"2023","journal-title":"Gastroenterol Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"De Lange","year":"2017","journal-title":"Nature Genet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"De Souza","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental risk factors for inflammatory bowel diseases: an umbrella review of Meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41575-023-00885-x","article-title":"Upgrading therapeutic ambitions and treatment outcomes","volume":"21","author":"Kotze","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ecco-jcc\/jjaa232","article-title":"Outcome of ulcerative colitis 20 years after diagnosis in a prospective population-based inception cohort from south-eastern Norway, the IBSEN study","volume":"15","author":"Monstad","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/apt.16202","article-title":"Colectomy rates for ulcerative colitis in England 2003-2016","volume":"53","author":"Worley","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig Dis Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.crphar.2022.100104","article-title":"Positioning biologics in the treatment of IBD: a practical guide - which mechanism of action for whom?","volume":"3","author":"Juillerat","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/MEG.0000000000002087","article-title":"Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients","volume":"33","author":"Tursi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"ii54\u201363","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality","volume":"16","author":"Atreya","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2024.2309300","article-title":"Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study","volume":"24","author":"Tursi","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/apt.16119","article-title":"Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy","volume":"52","author":"Panaccione","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.17294\/2330-0698.1722","article-title":"The inflammatory bowel disease questionnaire in randomized controlled trials of treatment for ulcerative colitis: systematic review and Meta-analysis","volume":"7","author":"Yarlas","year":"2020","journal-title":"J Patient Cent Res Rev"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.14309\/01.ajg.0000777044.92295.4d","article-title":"S878 patient reported outcomes (PRO2) are a sensitive measure of endoscopic disease activity in ulcerative colitis","volume":"116","author":"Lechner","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"175628482211363","DOI":"10.1177\/17562848221136331","article-title":"Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program","volume":"15","author":"Sandborn","year":"2022","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1458998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:36:29Z","timestamp":1726720589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1458998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":25,"alternative-id":["10.3389\/fmed.2024.1458998"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1458998","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1458998"}}